Dr Lal PathLabs

November 6, 2018

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex, Bandra (E)
Mumbai - 400051

The Bombay Stock Exchange Limited
15th Floor, Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai – 400001

Subject: Press Release for Unaudited Financial Results for the Quarter and Half Year ended September 30, 2018

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half Year ended September 30, 2018.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary & Legal Head

Dr Lal PathLabs Limited

Encl: As above

For Immediate Release **November 6, 2018**

Dr. Lal PathLabs Limited records revenue growth of 14.1% to Rs 3175 mn in Q2 FY2018-19

New Delhi, India, Nov 6, 2018 – Dr. Lal PathLabs Limited (referred to as the "Company"; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended September 30, 2018

Consolidated Performance Highlights: Q2FY2018-19 vs Q2FY2017-18
Revenue growth: 14.1% at Rs 3175 mn,
Normalised EBITDA at Rs 905 mn, PBT at Rs 881 mn
Normalised EBITDA margins at 28.5% vs 29% last year and
PAT Rs 574 mn with margin at 18.1%

- Operating Revenue increased by 14.1% in Q2 to Rs. 3175 million vs Rs 2781 million in the previous year same quarter. Underlying volume growth is 18.8% during the quarter.
- Normalised EBITDA in Q2FY19 grew 12% to Rs.905 million from Rs 808 million in the same quarter last year, after adjustment for RSU, other stock based compensation costs and CSR expense.
- EBITDA Margin at 28.5% for Q2 FY19 vs 29% in Q2 FY18.
- PBT was Rs 881 mn in Q2 vs Rs 778 mn in Q2 last year.
- Profit after Tax in Q2FY19 at Rs. 574 million as compared to Rs 509 million in Q2 last year.

Financial Overview (Consolidated) in Rs mn

Particulars	Q2 FY19	Q2 FY18	*Growth %*	YTD Sep'18	YTD Sep'17	*Growth %*
Total Revenue	**3,175**	**2,781**	***14.1%***	**6,098**	**5,274**	***15.6%***
Total Expenditure	2,307	2,003		4,479	3,840	
EBITDA	**868**	**779**	***11.5%***	**1,618**	**1,434**	***12.9%***
Adj for RSU, stock based comp. & CSR cost	37	29		80	54	
Normalised operating EBITDA	**905**	**808**	***12.1%***	**1,698**	**1,487**	***14.2%***
Normalised Margins	*28.5%*	*29.0%*		*27.8%*	*28.2%*	
Other income incl. interest	109	77		203	152	
PBT	**881**	**778**	***13.2%***	**1635**	**1438**	***13.6%***
Margins	*27.8%*	*28.0%*		*26.8%*	*27.3%*	
PAT	**574**	**509**	***12.8%***	**1071**	**953**	***12.3%***
Margins	*18.1%*	*18.3%*		*17.6%*	*18.1%*	
EPS (Basic)	**6.92**	**6.19**	***11.9%***	**12.93**	**11.59**	***11.6%***
EPS (Diluted)	**6.91**	**6.18**	***11.8%***	**12.91**	**11.57**	***11.5%***

About Dr. Lal PathLabs Limited

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

Dr. Lal PathLabs has built a national, "hub and spoke" network that includes its National Reference Laboratory in New Delhi, Regional Reference Lab in Kolkata and 191 other clinical laboratories, 2153 patient service centers and 5,624 pickup points as of March 31, 2018. Their customers include individual patients, hospitals and other healthcare providers and corporate customers.

Contact Details

Ved Prakash Goel
Dr. Lal PathLabs Limited
+91 124 3016500
cfo@lalpathlabs.com

Aparna Agarwal
Adfactors PR
+91 9811177405
aparna.agarwal@adfactorspr.com

For further information on Dr. Lal PathLabs see www.lalpathlabs.com

Safe Harbour

This release contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.